{"product_id":"lenvima-lenvatinib-4mg","title":"Lyvioni-10 (Lenvatinib)","description":"Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply.\r\n\u003ch3\u003eDifferentiated Thyroid Cancer\u003c\/h3\u003e\r\nIndicated for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC)\r\n\r\n24 mg (two 10 mg capsules and one 4 mg capsule) PO qDay\r\n\u003ch3\u003eRenal Cell Carcinoma\u003c\/h3\u003e\r\n\u003ch4\u003eCombination therapy with everolimus\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 18 mg (one 10 mg capsule and two 4 mg capsules) PO qDay PLUS\u003c\/li\u003e\r\n \t\u003cli\u003eEverolimus 5 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCombination therapy with pembrolizumab\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eIndicated in combination with pembrolizumab for first-line treatment of patients with advanced RCC\u003c\/li\u003e\r\n \t\u003cli\u003eLenvatinib 20 mg PO qDay, PLUS\u003c\/li\u003e\r\n \t\u003cli\u003ePembrolizumab 200 mg IV q3Weeks OR 400 mg q6Weeks\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression, unacceptable toxicity, or for pembrolizumab, up to 24 months in patients without disease progression\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eHepatocellular Carcinoma\u003c\/h3\u003e\r\nIndicated for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)\r\n\u003ch4\u003eDose based on actual body weight\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: 12 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eContinue until disease progression or until unacceptable toxicity\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eEndometrial Cancer\u003c\/h3\u003e\r\nIndicated in combination with pembrolizumab for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation\r\n\r\n20 mg PO qDay, PLUS pembrolizumab 200 mg IV q3weeks\r\n\r\nContinue until disease progression or unacceptable toxicity\r\n\r\nRefer to pembrolizumab prescribing information for recommended dosing information\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDTC dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 20 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRCC or endometrial carcinoma dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: Reduce to 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: Reduce to 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eDose modification of everolimus in RCC\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eReduce lenvatinib dose first and then the everolimus dose for adverse reactions of both lenvatinib and everolimus\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to the everolimus prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eDose modification of pembrolizumab in endometrial carcinoma\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eInterrupt one or both drugs or reduce lenvatinib when appropriate\u003c\/li\u003e\r\n \t\u003cli\u003eNo dose reductions are recommended for pembrolizumab\u003c\/li\u003e\r\n \t\u003cli\u003eRefer to pembrolizumab prescribing information for additional dose modification information\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHCC dose reductions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eFirst occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 8 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSecond occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eThird occurrence\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026lt;60 kg: Discontinue\u003c\/li\u003e\r\n \t\u003cli\u003e≥60 kg: Reduce to 4 mg PO every other day\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHypertension\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold if persists despite optimal antihypertensive therapy; resume at reduced dose when hypertension is controlled at Grade ≤2\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eCardiac dysfunction\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3: Withhold until improved Grade≤1or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eArterial thrombotic event\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHepatoxicity\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n \t\u003cli\u003eHepatic failure: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eProteinuria\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e≥2 g\/24 hr: Withhold; resume at reduced dose after resolution to \u0026lt;2 g\/24 hr\u003c\/li\u003e\r\n \t\u003cli\u003eNephrotic syndrome: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eGI toxicity\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 nausea, vomiting, and diarrhea: Withhold; resume at reduced dose after resolution to Grade ≤1 or baseline\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 nausea, vomiting, and diarrhea: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGI perforation, any grade: Permanently discontinue\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 3 or 4 GI fistula: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRenal failure or impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eGrade 3 or 4: Withhold until improved Grade ≤1 or baseline; resume at reduced dose or discontinue depending on severity and persistence of adverse reaction\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eQTc prolongation\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\u0026gt;500 ms or \u0026gt;60 ms increase from baseline: Withhold; resume at reduced dose after resolution to ≤480 ms or baseline\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eReversible posterior leukoencephalopathy syndrome (RPLS)\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eAny grade: Withhold until fully resolved, resume at reduced dose or discontinue depending on severity and persistence of neurologic symptoms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003ePersistent or intolerable Grade 2 or 3 adverse reaction, or Grade 4 laboratory abnormality: Withhold until improves to Grade ≤1 or baseline; resume at reduced dose\u003c\/li\u003e\r\n \t\u003cli\u003eGrade 4 adverse reaction: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eRenal impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (CrCl ≥30 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSevere (CrCl \u0026lt;30 mL\/min)\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eMild-to-moderate (Child-Pugh A or B): No dosage adjustment necessary\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eSevere (Child-Pugh C)\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eDTC: 14 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eRCC and endometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n \t\u003cli\u003eEndometrial carcinoma: 10 mg PO qDay\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946953771,"sku":"RL1420230901138","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-04-1767.jpg?v=1787022083","url":"https:\/\/xomeds.com\/products\/lenvima-lenvatinib-4mg","provider":"XOMEDS","version":"1.0","type":"link"}